Hilco Corporate Finance logo
To exceed customer expectations, Hilco Corporate Finance has carefully built our organization to go beyond the traditional investment banking services offered by thousands of competitors.
Learn More

Investment Banking Services

Hilco Corporate Finance will identify, evaluate, select and pursue the best options for each unique situation. Our team of experts will formulate value projections, identify counter parties, prepare marketing materials, and assist with the myriad of issues and decisions you may face within your unique situation. Our team of professionals will provide proven leadership and a global reach with a track record of success for middle market companies.

Learn More

Added Value Services

We create incremental value in the transaction process for Middle Market Companies. By taking advantage of our extensive platform of services, resident knowledge and global reach we work to identify the intrinsic value of the business asset, deliver a clear approach to maximize and monetize the value of that asset, and provide valuation services including lending, financial reporting, compliance, fairness opinions, tax, and dispute resolution.

Learn More

Middle Market Focus

For 30 years Hilco Global has focused on Middle Market customers. We understand the marketplace well. Our corporate finance organization focuses on transactions between $20 and $250 million for small and middle-market companies headquartered in North America and larger companies wishing to acquire, merge or divest divisions.

We are industry agnostic. We have significant experience in retail, consumer products, manufacturing, healthcare, business and professional services, financial services, automotive, energy, technology, among others.

Learn More


Exosect Offered for Sale by Hilco Streambank

Nov 02, 2018

Deadline for Submitting Bids Set for November 16, 2018 @ Noon BST

NY, November 1, 2018: Hilco Streambank is soliciting offers for the business and assets of Exosect Limited (in Administration) (“Exosect” or the “Company”), an innovative formulations business.

The Joint Administrators, Paul Masters and Conrad Beighton of Leonard Curtis Recovery Limited, have instructed Hilco Streambank to actively seek interested parties with regards to the sale of the business and assets of the Company, including its extensive intellectual property assets and proprietary know-how consisting of the understanding, experience and knowledge of Exosect’s highly skilled employees.

Since its formation in 1999 as a University of Southampton spin out, Exosect has been developing pioneering sustainable pest and disease control solutions to tackle a wide range of problems throughout the food supply chain. Over GB£25 million ($32 million) has been invested in the development of the Company’s valuable intellectual property. Its award-winning patented formulations technology (Entostat®), which is based on the use of electrostatically charged wax micro powders, assists with optimization and the direct transfer of active ingredients by electrostatically adhering to a range of surfaces including seeds, grains and pellets, insects and foliage, and building fabrics for improved efficacy, safety, and commercial viability.

With a recent focus on out-licensing, earlier this year, the Company negotiated a license with agrochemical multinational Monsanto for the use of the Entostat® technology for the delivery of select agricultural biologicals as seed treatments.

Having initially developed, marketed and sold pheromone-based products, the Company also continues to support two well-regarded products sold through distributors. Exosect’s moth control product is used by the UK Houses of Parliament and the Royal Opera House.

Hilco Streambank Director Nat Baldwin explained, “Exosect has been a market leader in its specialized area for nearly 20 years. Exosect’s technology platforms deliver a unique mix of commercial and environmental benefits and are underpinned by an extensive suite of patents and formulations expertise.”

The Company’s innovations are currently being commercialized through the £60 billion ($77 billion) crop protection and plant growth enhancement sector under license, but have potential use within many industrial sectors such as animals and public health.




Baldwin was confident of a return from the sales exercise, adding, “The team at Hilco Streambank has been conducting a comprehensive sales and marketing exercise which will continue over the coming weeks. We have received strong international interest in the business and expect a competitive bidding process.”

Parties interested in learning more about the Exosect acquisition opportunity should contact Hilco Streambank directly using the contact information provided below. Visit the Hilco Streambank website for more information regarding the opportunity: http://www.hilcostreambank.com/assets/exosect

Hilco Global will only use data you have agreed to share with us. You have the ability to view, change and delete data at any time upon request. Please view our privacy policy.

  Hilco Global | Asset Smarter

Visit Hilco Global to discover the full array of valuation, monetization and advisory business solutions.

Learn More